Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5171667
Max Phase: Preclinical
Molecular Formula: C43H71N15O9S2
Molecular Weight: 1006.27
Associated Items:
ID: ALA5171667
Max Phase: Preclinical
Molecular Formula: C43H71N15O9S2
Molecular Weight: 1006.27
Associated Items:
Canonical SMILES: CC(C)C[C@H](NC(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N1)C(N)=O
Standard InChI: InChI=1S/C43H71N15O9S2/c1-22(2)17-31(35(47)60)55-41(66)33-21-69-68-20-26(46)36(61)52-30(13-15-45)39(64)53-29(12-8-16-50-43(48)49)37(62)56-32(18-24-19-51-27-10-5-4-9-25(24)27)40(65)58-34(23(3)59)42(67)54-28(38(63)57-33)11-6-7-14-44/h4-5,9-10,19,22-23,26,28-34,51,59H,6-8,11-18,20-21,44-46H2,1-3H3,(H2,47,60)(H,52,61)(H,53,64)(H,54,67)(H,55,66)(H,56,62)(H,57,63)(H,58,65)(H4,48,49,50)/t23-,26+,28+,29+,30+,31+,32+,33+,34+/m1/s1
Standard InChI Key: IELFCHSTRNARKJ-XCEVRIASSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1006.27 | Molecular Weight (Monoisotopic): 1005.5001 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Liu J, Xu S, Huang C, Shen J, Yu S, Yu Y, Sun Q, Dai Q.. (2022) Synthesis and activity evaluation of selenazole-coupled CPI-1 irreversible bifunctional inhibitors for botulinum toxin A light chain., 73 [PMID:35914651] [10.1016/j.bmcl.2022.128913] |
Source(1):